News
Neupulse raises £3 million to accelerate delivery of its neurotherapeutic technology
Neupulse Press Release, Nottingham, UK - Neupulse, a neurotherapeutics company focused on delivering innovative solutions to people with brain health conditions, like Tourette Syndrome, has announced it has successfully raised £3 million in new funding. The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, with participation from existing and new investors. The funding will be used to scale sales and accelerate Neupulse’s path to market, supporting product development, regulatory progress and early commercialisation, to ensure the company’s technology reaches individuals who need it most. The funding comes at a time when venture and growth funding remains highly constrained, underscoring the strength of Neupulse’s proposition and the confidence investors have in both the company’s mission and execution. Neupulse’s continued momentum highlights growing demand for effective, clinically grounded neurotherapeutic solutions and positions Neupulse strongly for its next phase of growth. Neupulse’s product is designed to address critical gaps in current treatment options, combining scientific rigour with a clear focus on real-world impact. This funding round enables the company to move decisively from development towards commercial launch in mid-2026, while continuing to build the evidence base required by clinicians, regulators, and healthcare systems. The company first secured funding from the Midlands Engine Investment Fund II in 2024 to finalise development of a non-drug treatment to help manage the symptoms of Tourette’s Syndrome. The £500,000 investment helped Neupulse’s continued research into the TS therapy wristband device and clinical trials. Eos and Mercia Ventures are both experienced backers of high-growth healthcare and deep-tech businesses, bringing not only capital but strategic expertise to support Neupulse. Their continued leadership reflects a shared belief in the company’s long-term potential and its ability to generate both commercial and clinical value. Paul Cable, CEO, Neupulse said: “This investment underlines the unmet need in providing people with conditions like Tourette Syndrome a solution to manage their condition, and as a company, we are driven to improve the lives of individuals with these conditions.” Ian Rhodes, Chair of the board at Neupulse, added: “This is a great example of advanced biomedical research from a leading UK university creating an initial UK market launch during 2026. This will increasingly benefit the UK economy as the technology scales out globally.” David Tindall, Senior Investment Manager at the British Business Bank, said: “Neupulse’s growth over the past year, following investment from the Midlands Engine Investment Fund II, has been impressive. By addressing a clear gap in the market and delivering a much-needed solution for those affected, the business exemplifies the Fund’s commitment to backing ambitious, high-growth companies. This latest round of funding will further support Neupulse in developing and launching new treatment options.” Andrew McNeill, Investor Director at Eos, said: "We are delighted to support the next chapter of Neupulse as they move towards commercialisation. This is exactly the kind of company and science we like to back. Passionate founders and technology with the potential to positively impact the lives of people across the globe.” Sandy Reid, Fund Principal, Mercia Ventures added: “Tourette Syndrome is believed to affect up to two per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions. Neupulse’s device offers a genuine alternative that could transform lives.” The £400m Midlands Engine Investment Fund II covers the entire Midlands region and provides debt finance from £25k to £2m and equity investment up to £5m to help a range of small and medium sized businesses to start up, scale up or stay ahead. The purpose of the Midlands Engine Investment Fund II is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the Midlands. The Midlands Engine Investment Fund II will increase the supply and diversity of early-stage finance for smaller businesses in the Midlands, providing funds to firms that might otherwise not receive investment and help to break down barriers in access to finance. About Neupulse Neurotherapeutics Ltd was founded in 2021 as a spin-out from the University of Nottingham, commercialising the research of Professor Stephen Jackson, Professor Georgina Jackson and Dr Barbara Morera. We are a neurotechnology company pioneering non-invasive neuromodulation solutions to improve quality of life for people living with neurological and mental health conditions. Combining neuroscience and user-centric design, Neupulse develops wearable technologies that deliver effective and drug free solutions. Our mission is to make our neuromodulation therapies available to everyone, empowering individuals to take control of their neurological health. About Mercia Ventures Mercia Ventures is a proactive venture capital investor focused on being the first-choice partner for growth. Mercia Ventures makes equity investments of up to £10million across all sectors, with specialisms in Software, Consumer, Healthcare and Deep Tech. Mercia Ventures is a trading name of investment funds managed by Mercia Fund Management Limited and Mercia Regional Ventures Limited, part of the Mercia Asset Management PLC Group, and sits alongside the Group’s wider private equity, debt and proprietary balance sheet operations. The Group has 11 offices in the UK, and Mercia Ventures’ national footprint and 48 strong investment team draws on their experiences as founders, PhD scientists, software engineers, corporate financiers and management consultants to help our partner companies successfully achieve their ambitions. Mercia Asset Management PLC has c.£2 billion of assets under management. Mercia Asset Management PLC is quoted on AIM with the epic "MERC". The Group raises its own Venture Capital Trusts (VCTs) and Enterprise Investment Scheme (EIS) Funds, and details about open offers can be found through Mercia’s website. Mercia Asset Management PLC is quoted on AIM with the epic "MERC" and includes the following wholly owned subsidiaries: Mercia Fund Management Limited is authorised and regulated by the FCA under firm reference number 524856 Mercia Regional Ventures Limited is authorised and regulated by the FCA under firm reference number 183363 Mercia Business Loans Limited is authorised and regulated by the FCA under firm reference number 443560 Frontier Development Capital Limited is authorised and regulated by the FCA under firm reference number 829697 www.mercia.co.uk About the Midlands Engine Investment Fund II Operated by the British Business Bank, the Midlands Engine Investment Fund II (MEIF II) provides a mix of debt and equity funding. MEIF II offers a range of commercial finance options with small loans from £25k to £100k, debt finance from £100k to £2m and equity investment up to £5 million. It works alongside the Combined Authorities, Local Enterprise Partnerships (LEPs), and Growth Hubs, as well as local intermediaries such as accountants, fund managers and banks, to support smaller businesses in the Midlands at all stages of their development. The funds in which the MEIF II invests are open to businesses with material operations, or planning to open material operations, in the West and East and South East Midlands. Supported by Nations and Regions Investments Limited, a subsidiary of British Business Bank plc, the Bank is a development bank wholly owned by HM Government. Neither Nations and Regions Investments Limited nor British Business Bank plc are authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). For investment by MEIF II sub-fund at the investee company level. The investment from the Midlands Engine Investment Fund II into Neupulse does not amount to any endorsement or warranty from Nations and Regions Investments Limited, the British Business Bank plc or the government of the United Kingdom. About Eos Advisory Eos Advisory invests in and commercialises science and technology at local seed-stage, with the potential to scale globally, and with a focus on improving the health of people and the planet. Founded in St. Andrews in 2014, Eos is the trusted link between non-specialist Investors and highly specialist, knowledge intensive technology companies, building a portfolio of companies developing innovations to improve disease diagnostics, prevention, and treatment, environmental sustainability, and food and water security. Eos works in partnership with family offices, individuals, companies, and institutional investors who invest through an annual, EIS qualifying Innovation Fund, and an Investment Syndicate: https://eos-advisory.com
Learn more
I Swear Trailer Released: A True Tourette Syndrome Story Featuring Neupulse
The official trailer for I Swear, directed by BAFTA-nominated filmmaker Kirk Jones, has just been released and it’s nothing short of powerful. Set for release in UK cinemas on 10 October 2025, I Swear tells the extraordinary true story of John Davidson, a campaigner, speaker, and inspiration for the Tourette Syndrome community. For Neupulse, this movie is deeply personal on a few levels. Not only is John’s story close to our mission, but excitingly our technology also features in the film. A Story That Needed to Be Told The film charts John Davidson’s journey from a misunderstood teenager in a small Scottish town to an outspoken advocate for people living with Tourette Syndrome. Diagnosed at age 15, John faced isolation, ridicule, and even the threat of institutionalisation, at a time when very few understood what Tourette Syndrome actually was. His vocal and motor tics started to have a huge impact on his daily life, often misunderstood by peers, teachers, and even healthcare professionals. But I Swear isn’t just about struggle, it’s about resilience. It’s about the humour, heart, and community that helped John thrive despite the odds. It’s about finding the strength to live loudly and authentically. A Glimpse Into John’s World The official trailer, distributed by the film company StudioCanal, introduces us to John (played by Robert Aramayo) as a teenager trying to make sense of his rapidly changing body and mind. Highlighted in the trailer are situations John finds himself in time and time again. His tics affecting his home life, school, work and his place in the wider world. Amongst all these snapshots we see the full range of emotions that can come with tics. Anger, pain, rejection, humour, and so much more. As a viewer it's a rollercoaster too, being pulled between laughter (“Spunk for milk!”) and tears, the trailer perfectly setting the tone of a film that attempts to walk some fine lines. The film doesn’t shy away from John’s emotional struggles, but nor does it reduce him to them. This is a full, nuanced portrayal of a young man navigating misunderstanding and self-discovery. His story becomes not only one of survival but of transformation. A Stellar Line-up of British Talent Taking on the lead role is Robert Aramayo, best known for his performances in The Rings of Power and The King’s Man. Aramayo reportedly spent time with John Davidson and his family in Galashiels to understand his personality and mannerisms. His portrayal is already earning praise for its depth and sensitivity. Joining Aramayo are screen icons Maxine Peake as Dottie Achenbach, one of John’s key supporters. Shirley Henderson plays his mother Heather Davidson. The cast is rounded out by Peter Mullan, playing Tommy Trotter, a compassionate teacher who becomes instrumental in John’s life. This combination of talent, lived experience, and genuine heart gives I Swear the authenticity and emotional punch it needs. The Vision of Kirk Jones Director and writer Kirk Jones is no stranger to stories with heart. Known for hits like Waking Ned, Nanny McPhee, and My Big Fat Greek Wedding 2, Jones brings his signature warmth and understated humour to this emotionally charged script. Jones was reportedly moved by John Davidson’s story after watching a BBC documentary about him years ago. From there, he worked closely with John and his family to develop a screenplay that honoured their journey while making the story accessible to a wider audience. TS in the Spotlight One of the film’s most important achievements is its accurate, layered portrayal of Tourette Syndrome, a condition so often reduced to a punchline in popular culture. Instead of focusing only on coprolalia (the involuntary swearing many people wrongly assume defines the condition), I Swear digs into the daily experience of living with a neurological disorder that affects speech, movement, and self-image. It explores the impact not just on John, but on the people around him. For viewers unfamiliar with Tourette Syndrome, the film is an education. For those living with TS, it’s a representation of some of the challenges faced. And for everyone watching, it’s a call to empathy. Neupulse Part Of The Story We’re so proud to share that Neupulse plays a role in I Swear. Without revealing too much, we can confirm that our wearable neurotechnology - designed to help manage tics in people with Tourette Syndrome - is featured in the film. John has been a vital part of our journey at Neupulse. His insight, experience, and unfiltered honesty, along with other members of the TS community, has shaped the way we think about support, accessibility, and the lived experience of those with Tourette Syndrome. Why This Film Matters Representation in media matters. When real, honest stories are told, with empathy, humour, and respect, they have the power to shift public perception and inspire real change. I Swear is more than a film. It’s a testament to what happens when someone refuses to be silenced. It’s a reminder that behind every medical condition is a human being with dreams, fears, jokes, and stories to tell. And it’s a celebration of the progress being made, from outdated treatments and harmful stigma to innovation, visibility and hope. At Neupulse, we believe in empowering people with Tourette Syndrome, not just with devices, but with dignity. That’s why this film feels so important to us. Popcorn At The Ready We can't wait to watch the movie! The trailer for I Swear sets the stage for what promises to be one of the most moving and necessary British films of the year. With a talented cast, an acclaimed director, and a story grounded in truth, it’s a must-see for anyone who believes in the power of storytelling to drive change. We’re incredibly proud that Neupulse is part of this cinematic journey. We’ll be sharing more about how we feature in the film, and what it means for the community, in the coming months. Let us know what you think of the trailer and what moments stood out most. We’d love to hear from you. #ISwearFilm #Neupulse #TourettesAwareness #Neurodiversity #JohnDavidson #NeupulseInFilm
Learn more
Tourettes Action Launches #Misunderstood Campaign
From May 15th to June 15th, Tourettes Action (TA) is leading a powerful national campaign to shine a light on the reality of living with Tourette Syndrome (TS). Their boldest initiative yet, #Misunderstood, calls on everyone to reframe their understanding of TS and stand alongside the 300,000+ people in the UK affected by this often misjudged condition. Despite affecting 1 in 100 school-aged children – on par with Autism and epilepsy – Tourette Syndrome remains one of the most misunderstood neurological conditions. Too often, it’s reduced to inaccurate stereotypes or seen only through the lens of swearing. The truth is far more complex. TS is a lifelong, genetically based neurological condition that impacts both children and adults in deeply personal ways. A Campaign Rooted in Real Stories and Shared Voices The #Misunderstood campaign centres around a stirring music video that reimagines Nina Simone’s “Don’t Let Me Be Misunderstood.” Featuring 18-year-old Grace Cope and a choir of individuals living with TS, the film captures what it feels like to navigate daily life with the condition, including moments of frustration, strength, humour and resilience. “This is our most ambitious campaign yet,” said Emma McNally, CEO of Tourettes Action. “It’s not just about raising awareness. It’s about changing the story. For too long, people with TS have been judged or dismissed. We’re here to show the humanity behind the tics and invite the public to listen, learn and stand with us.” For Grace, who leads the choir in the video, the campaign is deeply personal: “Behind every tic is a person with dreams, talents, humour and heart. I hope that by sharing my story, more people can understand what Tourette’s really is and what it isn’t.” The choir members each bring their own story, united by a shared message. Understanding replaces stigma. For Billy Lockett, a The Voice finalist from Northamptonshire, the experience of singing with the choir was “wholesome and comforting,” showing just how powerful community can be. Their stories are honest, raw and moving. They remind us all that TS is more than a diagnosis – it’s a lived experience filled with challenge and strength, frustration and joy. Why Neupulse Supports This Campaign At Neupulse, we’re proud to support the mission of Tourettes Action. Like them, we believe that greater awareness leads to greater understanding and better support for those with TS. Our work developing non-invasive, wearable technology to help manage the symptoms of TS is driven by the same goals. Empowerment, dignity, and choice. We know that real change happens not just through innovation, but through empathy. That’s why campaigns like #Misunderstood matter. They humanise the condition, highlight the voices of people with TS and encourage all of us to listen more, judge less, and be more inclusive. How You Can Help Whether you live with TS, know someone who does, or are just beginning to learn, you can play a role this Tourette’s Awareness Month. Watch and share the #Misunderstood campaign film Use the hashtag #Misunderstood on social media to spread the message Host a conversation in your workplace or classroom Support the work of Tourettes Action through donations or volunteering Every action helps break down stigma and build a more understanding society. Visit Tourette's Action here to find out more about getting involved.
Learn more
Neupulse Attends Launch of N3 Centre for Neurotechnology, Neuromodulation and Neurotherapeutics
The University of Nottingham proudly celebrated the official opening of its Centre for Neurotechnology, Neuromodulation and Neurotherapeutics (N3), a major new initiative set to transform the future of brain health through cutting-edge innovation. The launch event, held on campus this week, brought together scientists and researchers from the centres team for insightful and inspiring talks about what the future holds. The N3 Centre marks a new chapter in brain health research and development, uniting world-class expertise in neurotechnology to accelerate the creation of devices that diagnose, manage and treat conditions such as Tourette Syndrome, dementia, depression and psychosis. The Centre builds on Nottingham’s global reputation in brain imaging and neuroscience and aims to translate scientific breakthroughs into real-world impact. As part of the event, attendees had the unique opportunity to preview our soon-to-be-released device, which uses non-invasive electrical stimulation to modulate brain activity and reduce tic severity. The Neupulse team was on hand to demonstrate the technology and answer questions. The N3 Centre will drive research across a range of exciting areas including state-of-the-art brain imaging, low-intensity ultrasound stimulation, closed-loop neuromodulation and wearable brain scanners. A key focus is making these technologies accessible and non-invasive, moving beyond traditional deep brain stimulation techniques to deliver safer, scalable alternatives. Director of the Centre and one of the Neupulse founders, Professor Stephen Jackson, addressed the audience, highlighting the urgent need for innovation in brain healthcare. With continued support from United Kingdom Research and Innovation (UKRI), the National Institute for Health and Care Research (NIHR) and leading research networks and with groundbreaking companies like Neupulse and Cerca Magnetics actively contributing to the ecosystem, the N3 Centre is positioned to be a national leader in advancing neurotechnology. The event was a powerful demonstration of the university’s and Neupulse's commitment to innovation, collaboration and improving lives. It set the tone for a future where brain health solutions are smarter, safer and more accessible to all. You can find out more about the N3 Centre here.
Learn more
Join Us for Tourette Talks: An Evening with World-Leading Tic Researchers
If you or someone you know is interested in the latest breakthroughs in Tourette Syndrome research, Tourette Talks is an event you won’t want to miss. Hosted by the University of Nottingham’s at the Institute of Mental Health, this free evening will bring together some of the world’s foremost experts in tic disorders for an engaging and insightful discussion. Whether you’re attending in person or tuning in online, you’ll gain firsthand insights into cutting-edge research, emerging therapies, and innovative technologies changing the landscape of Tourette Syndrome treatment. One of the highlights will be a presentation by Professor Stephen Jackson, a leading neuroscientist from the University of Nottingham and one of the driving forces behind Neupulse. His talk, 'Developing a wearable non-invasive brain stimulation device for tic disorder', will explore how science and technology are coming together to deliver real-world solutions for those living with tics. See below for full details of the event and how to join. Tourette Talks: An evening with tic researchers15th May 202516:30–19:00 BSTInstitute of Mental Health, University of Nottingham (or join online)Event Lineup: • Prof. John Piacentini (UCLA): Demystifying behavioural therapy for tics • Dr. Valerie Brandt (University of Southampton): Mechanisms of habit reversal training • Dr. Christine Conelea (University of Minnesota): Combining therapy with brain stimulation • Prof. Stephen Jackson (University of Nottingham): Wearable brain stimulation devices • Followed by a Q&A panel where you can ask your questions directly to the researchers Refreshments will be provided for in-person attendees. Free parking is available onsite from 4pm. How to Attend: • In-Person Tickets: Reserve here • Online Access: Register for the livestream herePlease note: the Q&A panel will not be streamed live This is an incredible opportunity to connect with researchers, ask your burning questions, and learn how science is shaping the future for people with Tourette Syndrome. We’d love to see you there - online or in Nottingham!
Learn more
Neupulse Featured in National ‘Unis Start Up The UK’ Campaign for Driving Innovation in Medtech
Neupulse has been featured in a new national campaign called ‘Unis Start Up The UK’, a Universities UK initiative highlighting the economic and social impact of university-supported start-ups across the country. A Surge in Innovation at the University of Nottingham Recent data shows a remarkable rise in spin-out activity at the University of Nottingham, with 29 companies launched between 2015 and 2025—more than triple the number from the previous decade. This growth showcases the university’s expanding role as a hub of innovation, supporting the development of technologies that address real-world problems in health, sustainability and digital industries. The university's support system includes Nottingham Technology Ventures (NTV), which helps researchers transform academic ideas into market-ready businesses. With nearly 40 spin-outs in its active portfolio, NTV plays a central role in nurturing early-stage companies with promising technologies—including Neupulse. Pioneering Non-Invasive Therapy for Tourette Syndrome The technology behind Neupulse is rooted in research from the University of Nottingham’s School of Psychology and School of Medicine, where scientists discovered that rhythmic median nerve stimulation (MNS) at the wrist could alter brain activity associated with involuntary movements. Clinical trials have shown that this stimulation significantly reduces tic frequency, intensity and the urge-to-tic in individuals with TS. Under the leadership of CEO Paul Cable, who helped spin the company out in 2021, Neupulse has gained support from both the university and private investors. The company has made significant strides toward market readiness and was recently highlighted in NICE’s draft guidance, which for the first time recommended digital therapies for conditions like TS—signalling a major step forward in treatment accessibility. National Recognition and Campaign Involvement Neupulse’s inclusion in the ‘Unis Start Up The UK’ campaign aligns with a broader national narrative: that universities are not only centres of learning, but also powerful engines for economic growth and innovation. The campaign, launched by Universities UK (UUK), celebrates the thousands of companies born from higher education institutions that contribute to jobs, investment and research-led solutions. According to national data, universities have helped create nearly 39,000 companies since 2015, with student start-up turnover rising by 757% and total employment from these businesses exceeding 64,000 jobs in 2022-23 alone. Vivienne Stern MBE, Chief Executive of UUK, emphasized the importance of supporting university enterprise: “The growth in university-supported start-ups over the last decade has been a staggering success. We can do more – both to encourage and support new businesses born in our universities and to ensure that they can remain in the UK and grow here.” Nottingham’s Broader Start-Up Ecosystem Beyond Neupulse, the University of Nottingham continues to foster entrepreneurship through initiatives like the Ingenuity Lab, which provides space, mentorship and funding to student and alumni entrepreneurs. Since its inception, the lab has supported the creation of 489 new ventures, with a focus on addressing social and environmental challenges. Additionally, Nottingham ranks second in the UK for turnover generated by student start-ups, which brought in over £400 million in 2022/23 alone. This vibrant entrepreneurial ecosystem positions the university as a national leader in transforming academic knowledge into societal impact. Looking Forward As Neupulse continues to develop its wearable technology for real-world use, its story stands as a powerful example of what university spin-outs can achieve with the right support, vision and scientific foundation. With plans to bring its first product to market by early 2026, Neupulse represents not only a beacon of innovation in medtech, but also a source of hope for individuals living with Tourette Syndrome and related neurological conditions. The recognition from ‘Unis Start Up The UK’ aligns with Neupulse's core mission: to turn cutting-edge research into practical tools that change lives. Read the full article here at The University of Nottingham website.
Learn more
Neupulse Nominated for Outstanding Achievement at 2025 Medilink Business Awards
We’re proud to announce that Neurotheraputics Ltd, the company behind Neupulse, has been officially named a finalist for the Outstanding Achievement Award at the Medilink Midlands Business Awards 2025, recognising our work in advancing wearable technology for neurological health. The awards, which celebrate innovation and excellence across the medtech and life sciences sectors, revealed this year’s finalists during a networking event held on 13th March in partnership with the West Midlands Health Tech Accelerator (WMHTIA). The event brought together businesses, innovators and thought leaders from across the region to recognise those making meaningful contributions to patient care and medical advancement. A Milestone Moment for Neupulse Our nomination in the Outstanding Achievement category is a significant milestone for the entire Neupulse team. It reflects the dedication, vision and collaboration that have gone into the development of our flagship wearable device — designed to reduce involuntary movements in individuals with Tourette Syndrome. Since launching our research and development efforts, Neupulse has remained focused on creating accessible, non-invasive and user-friendly technology that empowers users to regain control over their movement and daily routines. This recognition by Medilink Midlands serves as validation of that mission and highlights the potential impact our work could have on people’s lives. Celebrating Innovation in Health Tech The Medilink Midlands Business Awards are among the most prestigious accolades in the UK medtech landscape. Organised annually, the awards recognise excellence across a wide range of categories — from innovation and exporting, to sustainability and outstanding service delivery. The awards also shine a light on both start-ups and established organisations that are making meaningful strides in improving patient outcomes and transforming the healthcare system. Melanie Davidson, Chief Executive Officer at Medilink Midlands, commented on the calibre of this year’s nominees: “Congratulations to the finalists of the Medilink Midlands Business Awards 2025. Each year, we are inspired by the outstanding calibre of applications and this year is no exception. It is fantastic to celebrate the exceptional work taking place to drive innovation and improve patient outcomes. On behalf of the Medilink Midlands team, I wish all the finalists the best of luck and look forward to celebrating with them at the awards ceremony in May.” We are honoured to be among a list of inspiring organisations that are pushing the boundaries of health tech innovation, from academic research hubs to cutting-edge manufacturers. Where Innovation Meets Impact Neupulse’s nomination is particularly exciting as we prepare for a pivotal stage in our journey — the launch of our first product, planned for early 2026. This wearable wrist device is designed to provide real-time neuromodulation to help reduce tics and involuntary movements in individuals with Tourette Syndrome, backed by ongoing research and clinical studies. Our technology combines medical insight, wearable comfort and real-world usability to deliver an effective non-pharmaceutical option for those affected by neurological conditions. The nomination acknowledges not only the technological advancement behind the device but also the potential social impact — empowering individuals to live with greater freedom, confidence and control. Looking Ahead to the Awards Ceremony Winners will be announced during the Medilink Midlands Business Awards Ceremony on 15 May 2025, held at the Grand Station in Wolverhampton. The event, hosted by TV doctor and adventurer Dr Will Duffin, promises an evening of celebration, networking and entertainment with the region’s top innovators in life sciences and medtech. The Neupulse team will be in attendance, representing not just our own company, but also the wider community of researchers, engineers and participants who have contributed to our progress. A Shared Success This recognition would not be possible without the collaborative support of our trial participants and the incredible individuals who have shared their stories with us throughout the development process. It’s through their feedback and encouragement that we continue to refine and evolve our technology. We’re also incredibly grateful to our growing community of early supporters and prospective users who have joined us on this journey. Whether you’ve signed up to receive updates, taken part in clinical research or simply followed our story — this nomination is a shared success and we thank you for being a part of it. Join Us on the Journey We’ll be sharing updates as we approach the awards ceremony in May — and even more exciting milestones as we move closer to launch in 2026. If you’d like to stay connected, learn more about our research, or express interest in future clinical trials, we invite you to join our mailing list or get involved today. To learn more about the Medilink Midlands Business Awards and view the full list of 2025 finalists, visit medilinkmidlands.com.
Learn more
Dr Barbara Morera Presents at French Network for Tourette Syndrome Conference as Guest Speaker
Dr Barbara Morera, Chief Research Officer at Neupulse, recently delivered an inspiring presentation at the 17th annual meeting of the French Network for Tourette Syndrome. Dr Morera highlighted Neupulse's journey from groundbreaking research at the University of Nottingham to its current work advancing a non-invasive, wearable device aimed at reducing tics in individuals with Tourette Syndrome and Chronic Tic Disorder. Her talk emphasized Neupulse’s commitment to making the device widely accessible. The audience showed strong interest in the potential of Neupulse’s wearable device, underscoring the impact this innovation could have on improving lives and expanding treatment options for individuals with tic disorders. About the company Since incorporation in February 2021 Neupulse has achieved several significant milestones including development of a prototype device for use in a double-blind study. This double-blind, sham-controlled trial completed recruitment of more than 130 individuals with Tourette Syndrome in 2022 testing new and exciting wrist stimulation research designed by some of the world’s leading neuroscientists. The company has completed analysing the data from the trial with the results published in Q2 2023. The company is currently working on the development of the commercially available device. About Tourette Syndrome Tourette Syndrome is an often-debilitating condition that effects millions of individuals around the world. Tourette Syndrome almost always starts in early childhood meaning individuals with the condition are typically young children. Tourette Syndrome causes sufferers to make involuntary sounds and movements called tics that can be painful, embarrassing and difficult if not impossible to control. The majority of individuals with the condition also have other taxing co-occurring conditions such as attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD) and anxiety. Many individuals with Tourette Syndrome have high intelligence, quick wit and are artistic and have other exceptional abilities yet the condition is still stigmatised and they are poorly understood by the public and even by medical professionals often leading to challenging social lives for those with the condition. While many with Tourette Syndrome find that their tics and other symptoms improve as they move into adulthood this is not always the case and the negative effects of dealing with the condition during school years can be significant for both individuals and their families. There is no cure for Tourette Syndrome and current medications and treatment options are of limited and questionable availability and efficacy. Neupulse is excited to continue to work towards becoming the first truly effective, non-invasive treatment option for those with the condition which is believed to affect more than 1.5% of the world’s population or 120 million people and more than 2% of the world’s children or 40 million children.
Learn more
Neupulse secures more funding to advance world’s first wearable device to tackle Tourette Syndrome
Neupulse has secured more funding to advance the world’s first wearable device aimed at tackling Tourette Syndrome (TS) and other tic disorders towards commercialisation through the Midlands Engine Investment Fund II, facilitated by appointed fund manager for the East and South East Midlands, Mercia Ventures. This follows a £2.5M investment earlier this year and brings the total the company has raised to date to almost £4.5m. Paul Cable CEO of Neupulse said: “This funding from Midlands Engine Investment Fund II will take us one step further towards our mission to roll out our device and give new hope to people with Tourette's. Having Mercia Ventures on board as a partner provides additional value, given its expertise in backing businesses that are developing new products and helping them gain entry to the US market.” Sandy Reid of Mercia Ventures added: "Tourette Syndrome is believed to affect up to 2 per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions. Neupulse's device offers a genuine alternative. This funding will help the company to bring it to market and transform lives.”
Learn more